@Poor Lack of management credibility is an issue to the investment community and is one reason people (pharma) does not take the Dcvax product line seriously. Too many innuendos with no follow through. Eventually the company will either release unblinded results which support FDA approval or the company goes BR. Currently the company does not have much money.
News 
Market Data 
Discover 
AI
